538 related articles for article (PubMed ID: 9168821)
21. Role of activated protein C in facilitating basement membrane invasion by tumor cells.
Kobayashi H; Moniwa N; Gotoh J; Sugimura M; Terao T
Cancer Res; 1994 Jan; 54(1):261-7. PubMed ID: 8261450
[TBL] [Abstract][Full Text] [Related]
22. Haemostatic factors occupy new territory: the role of the urokinase receptor system and kininogen in inflammation.
Chavakis T; Kanse SM; May AE; Preissner KT
Biochem Soc Trans; 2002 Apr; 30(2):168-73. PubMed ID: 12023845
[TBL] [Abstract][Full Text] [Related]
23. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.
Schroeck F; Arroyo de Prada N; Sperl S; Schmitt M; Viktor M
Biol Chem; 2002; 383(7-8):1143-9. PubMed ID: 12437099
[TBL] [Abstract][Full Text] [Related]
24. Expression of urokinase-type plasminogen activator receptor is correlated with metastases of lingual squamous cell carcinoma.
Wang J; Guo F; Wei H; Dong J; Wu J
Br J Oral Maxillofac Surg; 2006 Dec; 44(6):515-9. PubMed ID: 16356605
[TBL] [Abstract][Full Text] [Related]
25. Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins.
Reuning U; Magdolen V; Hapke S; Schmitt M
Biol Chem; 2003 Aug; 384(8):1119-31. PubMed ID: 12974381
[TBL] [Abstract][Full Text] [Related]
26. Plasminogen activator mediated degradation of subendothelial extracellular matrix by human squamous carcinoma cell lines.
Niedbala MJ; Sartorelli AC
Cancer Commun; 1990; 2(5):189-99. PubMed ID: 2142433
[TBL] [Abstract][Full Text] [Related]
27. [Plasminogen activator-inhibitor 1: biochemical, structural and functional studies].
Declerck P
Verh K Acad Geneeskd Belg; 1993; 55(5):457-73. PubMed ID: 8128782
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
29. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration.
Zhou A; Huntington JA; Pannu NS; Carrell RW; Read RJ
Nat Struct Biol; 2003 Jul; 10(7):541-4. PubMed ID: 12808446
[TBL] [Abstract][Full Text] [Related]
30. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent.
Devy L; Blacher S; Grignet-Debrus C; Bajou K; Masson V; Gerard RD; Gils A; Carmeliet G; Carmeliet P; Declerck PJ; Nöel A; Foidart JM
FASEB J; 2002 Feb; 16(2):147-54. PubMed ID: 11818362
[TBL] [Abstract][Full Text] [Related]
31. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.
Waltz DA; Natkin LR; Fujita RM; Wei Y; Chapman HA
J Clin Invest; 1997 Jul; 100(1):58-67. PubMed ID: 9202057
[TBL] [Abstract][Full Text] [Related]
32. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin.
Stefansson S; Lawrence DA
Nature; 1996 Oct; 383(6599):441-3. PubMed ID: 8837777
[TBL] [Abstract][Full Text] [Related]
33. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.
Czekay RP; Aertgeerts K; Curriden SA; Loskutoff DJ
J Cell Biol; 2003 Mar; 160(5):781-91. PubMed ID: 12615913
[TBL] [Abstract][Full Text] [Related]
34. Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis.
Praus M; Collen D; Gerard RD
Int J Cancer; 2002 Dec; 102(6):584-91. PubMed ID: 12447999
[TBL] [Abstract][Full Text] [Related]
35. Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations.
Chazaud B; Ricoux R; Christov C; Plonquet A; Gherardi RK; Barlovatz-Meimon G
Am J Pathol; 2002 Jan; 160(1):237-46. PubMed ID: 11786417
[TBL] [Abstract][Full Text] [Related]
36. Loss of the metastatic phenotype by a human epidermoid carcinoma cell line, HEp-3, is accompanied by increased expression of tissue inhibitor of metalloproteinase 2.
Testa JE
Cancer Res; 1992 Oct; 52(20):5597-603. PubMed ID: 1327511
[TBL] [Abstract][Full Text] [Related]
37. RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1.
Madsen JB; Dupont DM; Andersen TB; Nielsen AF; Sang L; Brix DM; Jensen JK; Broos T; Hendrickx ML; Christensen A; Kjems J; Andreasen PA
Biochemistry; 2010 May; 49(19):4103-15. PubMed ID: 20387790
[TBL] [Abstract][Full Text] [Related]
38. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness.
Blasi F
Bioessays; 1993 Feb; 15(2):105-11. PubMed ID: 8385942
[TBL] [Abstract][Full Text] [Related]
39. Monoclonal antibody and synthetic peptide inhibitors of human tumor cell migration.
Yamada KM; Kennedy DW; Yamada SS; Gralnick H; Chen WT; Akiyama SK
Cancer Res; 1990 Aug; 50(15):4485-96. PubMed ID: 2369727
[TBL] [Abstract][Full Text] [Related]
40. Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer.
Lobov S; Ranson M
Cancer Lett; 2011 Apr; 303(2):118-27. PubMed ID: 21316840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
